Corrigendum to Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: A multicentre, randomised, double-blind, placebo-controlled phase 3 trial [Ann Oncol, Vol 24, (2013) 1067-1073] doi: 10.1093/annonc/mds541;Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: A multicentre, randomised, double-blind, placebo-controlled phase 3 trial

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 1067-1073

  Saito, H ^a   Yoshizawa, H ^b   Yoshimori, K ^c   Katakami, N ^d   Katsumata, N ^e   Kawahara, M ^f   Eguchi, K ^g  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^c Japan Anti Tuberculosis Association   (Japan)

^d INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^e NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^f Otemae Hospital   (Japan)

^g TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy induced nausea and vomiting; CYP3A4; Fosaprepitant; Single dose; Substance P

Indexed keywords

CISPLATIN; DEXAMETHASONE SODIUM PHOSPHATE; FOSAPREPITANT; GRANISETRON; PLACEBO;

ADULT; AGED; ANEMIA; ARTICLE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HICCUP; HUMAN; INJECTION SITE DISCOLORATION; INJECTION SITE ERYTHEMA; INJECTION SITE EXTRAVASATION; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA BLOOD LEVEL;

EID: 84875628814     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt534     Document Type: Erratum

References (21)

1. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358: 2482-2494.
2. Basch E, Prestrud AA, Hesketh PJ et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29: 4189-4198.
3. Roila F, Herrstedt J, Aapro M et al. ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21(Suppl. 5): 232-243.
4. NCCN Clinical Practice Guidelines in Oncology™. Antiemesis V.1. 2012.
5. Hale JJ, Mills SG, MacCoss M et al. Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J Med Chem 2000; 43: 1234-1241.
6. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754030 Antiemetic Trials Group. N Engl J Med 1999; 340: 190-195.
7. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 2008; 112: 2080-2087.
8. Grunberg SM, Dugan M, Muss H et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 2009; 17: 589-594.
9. Lasseter KC, Gambale J, Jin B et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 2007; 47: 834-840.
10. Grunberg S, Chua D, Maru A et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 2011; 29: 1495-1501.
11. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol 2006; 24: 2932-2947 [Erratum in: J Clin Oncol 2006; 24: 5341-5342].
12. McCrea JB, Majumdar AK, Goldberg MR et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003; 74: 17-24.
13. Marbury TC, Ngo PL, Shadle CR et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol 2011; 51: 1712-1720.
14. Takahashi T, Hoshi E, Takagi M et al. Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving highdose cisplatin. Cancer Sci 2010; 101: 2455-2461.
15. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-4119.
16. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, doubleblind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090-3098.
17. Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006; 17: 1000-1006.
18. Grunberg SM, Rolski J, Strausz J et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 549-558.
19. Grunberg SM, Deuson RR, Mavros P et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004; 100: 2261-2268.
20. Warr DG, Grunberg SM, Gralla RJ et al. The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005; 41: 1278-1285.
21. Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol 2010; 21: 2316-2323.